|HCV NS5B 1a||HCV NS5B 1b|
|0.94 μM||1.2 μM|
|In vitro (25°C)||DMSO||89 mg/mL (199.72 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||89 mg/mL (199.72 mM)|
|In vivo||30% PEG400/0.5% Tween80/5% propylene glycol||30 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||22.44 mL||112.21 mL||224.42 mL|
|0.5 mM||4.49 mL||22.44 mL||44.88 mL|
|1 mM||2.24 mL||11.22 mL||22.44 mL|
|5 mM||0.45 mL||2.24 mL||4.49 mL|
*The above data is based on the productmolecular weight 445.6 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
Ciluprevir is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease.
Boceprevir is a protease inhibitor used as a treatment for hepatitis C genotype 1.
Telaprevir (VX-950) is known as protease inhibitors that inhibits the hepatitis C virus NS3.4A serine protease.
BMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R…